Casdin Capital 13F holdings, Q4 2016
Holdings as of December 31, 2016 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 25 US equity positions worth $121.1m in its Q4 2016 13F filing. The largest position was SG7 at 10.9% of the reported book, followed by LOXO ONCOLOGY INC and AGIO. Against the Q3 2016 filing, it opened 6 new positions, added to 12 and reduced 6 among the top 25 holdings.
What did Casdin Capital own in Q4 2016? Top 25 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2016 |
|---|---|---|---|---|---|---|---|
| 1 | SG7 SAGE THERAPEUTICS INC | 10.9% | $13.2m | 259,500 | -3% | reduced | |
| 2 | LOXO ONCOLOGY INC | 9.5% | $11.6m | 360,000 | 24% | added | |
| 3 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 8.3% | $10.0m | 240,500 | -15% | reduced |
| 4 | FOUNDATION MEDICINE INC | 8.0% | $9.7m | 546,000 | 32% | added | |
| 5 | EVH EVOLENT HEALTH INC | Healthcare | 6.8% | $8.2m | 555,000 | 44% | added |
| 6 | 2655787D BLUEPRINT MEDICINES CORP | 5.7% | $6.9m | 244,500 | -15% | reduced | |
| 7 | SPARK THERAPEUTICS INC | 5.3% | $6.4m | 128,500 | 37% | added | |
| 8 | GNMK GENMARK DIAGNOSTICS INC | 5.2% | $6.2m | 510,000 | -18% | reduced | |
| 9 | BLUEBIRD BIO INC | 4.2% | $5.1m | 82,500 | 38% | added | |
| 10 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 4.1% | $4.9m | 385,000 | 39% | added |
| 11 | GLOBAL BLOOD THERAPEUTICS IN | 3.6% | $4.4m | 304,000 | 27% | added | |
| 12 | KITE PHARMA INC | 3.5% | $4.2m | 94,000 | 4% | added | |
| 13 | MYOKARDIA INC | 2.8% | $3.4m | 265,000 | 66% | added | |
| 14 | EPIZYME INC | 2.7% | $3.3m | 275,000 | -7% | reduced | |
| 15 | ILMN ILLUMINA INC | Healthcare | 2.6% | $3.2m | 25,000 | – | new |
| 16 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 2.6% | $3.2m | 85,000 | 118% | added |
| 17 | CERNER CORP | 2.5% | $3.1m | 65,000 | – | new | |
| 18 | MDRX ALLSCRIPTS HEALTHCARE SOLUTN | Healthcare | 2.4% | $2.9m | 280,000 | 40% | added |
| 19 | AMYRIS INC | 2.1% | $2.5m | 3,425,000 | – | new | |
| 20 | SYROS PHARMACEUTICALS INC | 1.8% | $2.2m | 182,141 | 264% | added | |
| 21 | AEVI GENOMIC MEDICINE INC | 1.6% | $1.9m | 375,000 | – | new | |
| 22 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 1.2% | $1.4m | 127,500 | 0% | held |
| 23 | XLRN ACCELERON PHARMA INC | 0.9% | $1.1m | 45,000 | – | new | |
| 24 | EDIT EDITAS MEDICINE INC | Healthcare | 0.9% | $1.1m | 65,000 | -24% | reduced |
| 25 | GILD GILEAD SCIENCES INC | Healthcare | 0.7% | $895.0k | 12,500 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.